Clinical Trials

For a quick look at enrolling or soon to be enrolling investigational drug studies in Duchenne and their enrollment criteria, check out our Clinical Trial Cheat Sheet below.

Clinical Trial Finder

Use this Clinical Trial Finder below that can help provide you with more information regarding clinical trials in Duchenne that that you, your child, or your patient may be eligible for!

Watch Jett Foundation's Mini Satellite Presentation

Emerging Therapies for Duchenne Muscular Dystrophy

Presented by Jean Mah, M.D., Associate Professor of Pediatric Neurology Alberta Children’s Hospital at the 2016 Child Neurology Society Meeting to learn more about these potential therapies!

Latest Duchenne News

May 3, 2024

Pfizer Community Letter Announcing FDA Regenerative Medicine Advanced Therapy Designation to Fordadistrogene Movaparvovec

Pfizer shares that FDA has granted RMAT designation for gene therapy in development for Duchenne.

April 26, 2024

Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy

Capricor Therapeutics announces update on next steps for the Biologics License Application submission with its lead asset CAP-1002 in treating Duchenne muscular dystrophy.

April 23, 2024

BioMarin Clinical Trial Program Update for Duchenne Muscular Dystrophy

BioMarin shares updates on their Clinical Trial Programs.

April 17, 2024

Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy

Edgewise shares positive two-year topline results from the ARCH trial.

April 1, 2024

Pfizer Launches Caregiver Educational Platform Reimagine Duchenne

Pfizer launches Duchenne caregiver education website.

March 22, 2024

FDA Approves Nonsteroidal Treatment for Duchenne Muscular Dystrophy

Jett Foundation is thrilled to share that the U.S. Food and Drug Administration (FDA) has approved Duvyzat (givinostat) to treat children and adolescents with Duchenne muscular dystrophy (DMD). Please read...

Jett Foundation, Inc.
65 Cordage Park Circle
Suite 130 | Plymouth, MA 02360
781-585-5566 | info@jettfoundation.org

Sitemap

Support Jett Foundation

Jett Foundation, Inc. is a 501(c)3 registered tax-exempt nonprofit organization. Our Federal Tax ID is 04-3563445.

Stay Connected With Us

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Programs

Events